NOS3 and colorectal cancer: We previously described the role of endothelial nitric oxide synthase (eNOS) polymorphisms as possible predictive biomarkers of B efficacy11 in patients enrolled in the ITACa (Italian Trial in Advanced Colorectal Cancer) trial, a prospective randomized phase III multicentric study designed to investigate the role of B treatment in mCRC patients12.